NEW YORK, June 25 -- PolyGenyx, a Worcester, Mass., haplotyping startup, announced today that it has received a $997,673 Phase II Small Business Innovative Research grant from the National Human Genome Research Institute.

The company plans to use the grant, which spans two years, on development of HaploScan, its haplotyping platform, and develop haplotyping assays for the platform that can be commercialized.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.